Hybrid molecules based on 1,3,5-triazine as potential therapeutics: A focused review

Parteek Prasher; Mousmee Sharma; Alaa A.A. Aljabali; Gaurav Gupta; Poonam Negi; Deepak N. Kapoor; Inderbir Singh; Flavia C. Zacconi; Terezinha de Jesus Andreoli Pinto; Mateus Webba da Silva; Hamid A. Bakshi; Dinesh Kumar Chellappan; Murtaza M. Tambuwala; Kamal Dua

doi:10.1002/ddr.21704

Hybrid molecules based on 1,3,5-triazine as potential therapeutics: A focused review

Parteek Prasher
, Mousmee Sharma
, Alaa A.A. Aljabali
, Gaurav Gupta
, Poonam Negi
, Deepak N. Kapoor
, Inderbir Singh
, Flavia C. Zacconi
, Terezinha de Jesus Andreoli Pinto
, Mateus Webba da Silva
, Hamid A. Bakshi
, Dinesh Kumar Chellappan
, Murtaza M. Tambuwala
, Kamal Dua

Guru Nanak Dev University
University of Petroleum and Energy Studies
Uttaranchal University
Yarmouk University
Suresh Gyan Vihar University
Shoolini University of Biotechnology and Management Sciences
Chitkara University
Pontificia Universidad Católica de Chile
Universidade de São Paulo
Ulster University
International Medical University
University of Technology Sydney
University of Newcastle
Royal Prince Alfred Hospital

Research output: Contribution to journal › Review article › peer-review

30 Scopus citations

Abstract

Majority of the representative drugs customarily interact with multiple targets manifesting unintended side effects. In addition, drug resistance and over expression of the cellular efflux-pumps render certain classes of drugs ineffective. With only a few innovative formulations in development, it is necessary to identify pharmacophores and novel strategies for creating new drugs. The conjugation of dissimilar pharmacophoric moieties to design hybrid molecules with an attractive therapeutic profile is an emerging paradigm in the contemporary drug development regime. The recent decade witnessed the remarkable biological potential of 1,3,5-triazine framework in the development of various chemotherapeutics. The appending of the 1,3,5-triazine nucleus to biologically relevant moieties has delivered exciting results. The present review focuses on 1,3,5-triazine based hybrid molecules in the development of pharmaceuticals.

Original language	English
Pages (from-to)	837-858
Number of pages	22
Journal	Drug Development Research
Volume	81
Issue number	7
DOIs	https://doi.org/10.1002/ddr.21704
State	Published - Nov 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

1,3,5-triazine
anti-Alzheimer's activity
anti-inflammatory activity
anticancer activity
antimicrobial activity
antiplasmodial activity
hybrids
multidrug-resistance

Access to Document

10.1002/ddr.21704

Cite this

Prasher, P., Sharma, M., Aljabali, A. A. A., Gupta, G., Negi, P., Kapoor, D. N., Singh, I., Zacconi, F. C., de Jesus Andreoli Pinto, T., da Silva, M. W., Bakshi, H. A., Chellappan, D. K., Tambuwala, M. M., & Dua, K. (2020). Hybrid molecules based on 1,3,5-triazine as potential therapeutics: A focused review. Drug Development Research, 81(7), 837-858. https://doi.org/10.1002/ddr.21704

@article{35ccf94dad8f4bb487c46c2f9492c7b8,

title = "Hybrid molecules based on 1,3,5-triazine as potential therapeutics: A focused review",

abstract = "Majority of the representative drugs customarily interact with multiple targets manifesting unintended side effects. In addition, drug resistance and over expression of the cellular efflux-pumps render certain classes of drugs ineffective. With only a few innovative formulations in development, it is necessary to identify pharmacophores and novel strategies for creating new drugs. The conjugation of dissimilar pharmacophoric moieties to design hybrid molecules with an attractive therapeutic profile is an emerging paradigm in the contemporary drug development regime. The recent decade witnessed the remarkable biological potential of 1,3,5-triazine framework in the development of various chemotherapeutics. The appending of the 1,3,5-triazine nucleus to biologically relevant moieties has delivered exciting results. The present review focuses on 1,3,5-triazine based hybrid molecules in the development of pharmaceuticals.",

keywords = "1,3,5-triazine, anti-Alzheimer's activity, anti-inflammatory activity, anticancer activity, antimicrobial activity, antiplasmodial activity, hybrids, multidrug-resistance",

author = "Parteek Prasher and Mousmee Sharma and Aljabali, \{Alaa A.A.\} and Gaurav Gupta and Poonam Negi and Kapoor, \{Deepak N.\} and Inderbir Singh and Zacconi, \{Flavia C.\} and \{de Jesus Andreoli Pinto\}, Terezinha and \{da Silva\}, \{Mateus Webba\} and Bakshi, \{Hamid A.\} and Chellappan, \{Dinesh Kumar\} and Tambuwala, \{Murtaza M.\} and Kamal Dua",

note = "Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals, lnc.",

year = "2020",

month = nov,

doi = "10.1002/ddr.21704",

language = "English",

volume = "81",

pages = "837--858",

journal = "Drug Development Research",

issn = "0272-4391",

publisher = "John Wiley \& Sons Inc.",

number = "7",

}

TY - JOUR

T1 - Hybrid molecules based on 1,3,5-triazine as potential therapeutics

T2 - A focused review

AU - Prasher, Parteek

AU - Sharma, Mousmee

AU - Aljabali, Alaa A.A.

AU - Gupta, Gaurav

AU - Negi, Poonam

AU - Kapoor, Deepak N.

AU - Singh, Inderbir

AU - Zacconi, Flavia C.

AU - de Jesus Andreoli Pinto, Terezinha

AU - da Silva, Mateus Webba

AU - Bakshi, Hamid A.

AU - Chellappan, Dinesh Kumar

AU - Tambuwala, Murtaza M.

AU - Dua, Kamal

PY - 2020/11

Y1 - 2020/11

N2 - Majority of the representative drugs customarily interact with multiple targets manifesting unintended side effects. In addition, drug resistance and over expression of the cellular efflux-pumps render certain classes of drugs ineffective. With only a few innovative formulations in development, it is necessary to identify pharmacophores and novel strategies for creating new drugs. The conjugation of dissimilar pharmacophoric moieties to design hybrid molecules with an attractive therapeutic profile is an emerging paradigm in the contemporary drug development regime. The recent decade witnessed the remarkable biological potential of 1,3,5-triazine framework in the development of various chemotherapeutics. The appending of the 1,3,5-triazine nucleus to biologically relevant moieties has delivered exciting results. The present review focuses on 1,3,5-triazine based hybrid molecules in the development of pharmaceuticals.

AB - Majority of the representative drugs customarily interact with multiple targets manifesting unintended side effects. In addition, drug resistance and over expression of the cellular efflux-pumps render certain classes of drugs ineffective. With only a few innovative formulations in development, it is necessary to identify pharmacophores and novel strategies for creating new drugs. The conjugation of dissimilar pharmacophoric moieties to design hybrid molecules with an attractive therapeutic profile is an emerging paradigm in the contemporary drug development regime. The recent decade witnessed the remarkable biological potential of 1,3,5-triazine framework in the development of various chemotherapeutics. The appending of the 1,3,5-triazine nucleus to biologically relevant moieties has delivered exciting results. The present review focuses on 1,3,5-triazine based hybrid molecules in the development of pharmaceuticals.

KW - 1,3,5-triazine

KW - anti-Alzheimer's activity

KW - anti-inflammatory activity

KW - anticancer activity

KW - antimicrobial activity

KW - antiplasmodial activity

KW - hybrids

KW - multidrug-resistance

UR - https://www.scopus.com/pages/publications/85087217639

U2 - 10.1002/ddr.21704

DO - 10.1002/ddr.21704

M3 - Review article

C2 - 32579723

AN - SCOPUS:85087217639

SN - 0272-4391

VL - 81

SP - 837

EP - 858

JO - Drug Development Research

JF - Drug Development Research

IS - 7

ER -

Hybrid molecules based on 1,3,5-triazine as potential therapeutics: A focused review

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this